The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of dexamethasone (DEX) dose modification on osteonecrosis (ON) risk associated with intensified therapies for standard risk acute lymphoblastic leukemia (SR-ALL): A report from the Children’s Oncology Group (COG) study AALL0331.
Leonard A. Mattano
No relevant relationships to disclose
Meenakshi Devidas
No relevant relationships to disclose
Alison M. Friedmann
No relevant relationships to disclose
Elizabeth A. Raetz
No relevant relationships to disclose
Stephen Hunger
No relevant relationships to disclose
Naomi Joan Winick
No relevant relationships to disclose
William L. Carroll
No relevant relationships to disclose
Kelly W. Maloney
No relevant relationships to disclose